Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572817 · ClinicalTrials.gov registry record · Phase 3
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
A Phase 3 study of Influenza A Virus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT02572817 is a Phase 3 study of Influenza A Virus Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 138 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT02572817, a Phase 3 study of Influenza A Virus Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.
Conditions Studied
Interventions
- BIOLOGICAL High-titer anti-influenza plasma
- BIOLOGICAL Low-titer anti-influenza plasma
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- University of Massachusetts Medical School - Worcester
Michigan
- University of Michigan - Ann Arbor
- Beaumont Hospital - Royal Oak - Royal Oak
- Beaumont Hospital, Troy - Troy
California
- UCLA Pediatrics Infectious Diseases - Los Angeles
- Naval Medical Center San Diego (NMCSD) - San Diego
Colorado
- Children's Hospital Colorado - Aurora
- University of Colorado Denver - Aurora
Maryland
- University of Maryland Medical Center - Baltimore
- Johns Hopkins University - Baltimore
Arizona
- University of Arizona Health Sciences Center - Tucson
Connecticut
- Bridgeport Hospital - Bridgeport
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-05-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02572817
The ClinicalTrials.gov registry entry for NCT02572817 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza A Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which High-titer anti-influenza plasma is the first listed.
NCT02572817 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT02572817 about?
NCT02572817 is a clinical study titled "Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A". This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.
What is the current status of trial NCT02572817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2015-11. Estimated completion is 2018-05-18.
What conditions does trial NCT02572817 study?
This clinical trial studies the following conditions: Influenza A Virus Infection.
What interventions are being tested in trial NCT02572817?
The interventions under investigation include: High-titer anti-influenza plasma (BIOLOGICAL), Low-titer anti-influenza plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT02572817?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02572817 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.